Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Weighted-average common shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Trading Arrangement: Trading Arrangement [Axis] Maximum Maximum [Member] Statistical Measurement Statistical Measurement [Domain] Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash Summary Of Reconciliation Of Cash Cash Equivalents And Restricted Cash [Table Text Block] Summary of reconciliation of cash cash equivalents and restricted cash. Title of 12(b) Security Title of 12(b) Security Net income - diluted Net Income (Loss) Available to Common Stockholders, Diluted Document Fiscal Year Focus Document Fiscal Year Focus Acquisition-related costs Business Combination, Acquisition-Related Cost, Expense Number of non-clinical stage compounds Number Of Non-clinical Stage Compound Number Of Non-clinical Stage Compound Adjustment to Compensation, Amount Adjustment to Compensation Amount Financial Instrument Financial Instrument [Axis] Customer [Axis] Customer [Axis] Segment Reporting [Abstract] Other assets Disposal Group, Including Discontinued Operation, Other Assets Schedule of Financial Assets Measured at Fair Value on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Common stock, $0.001 par value; 220.0 shares authorized; 101.6 and 100.1 shares issued and outstanding, respectively Common Stock, Value, Issued 2027 Lessee, Operating Lease, Liability, to be Paid, Year One Work In Process Work In Process [Member] Work In Process Taxes paid related to net share settlement of equity awards Payment, Tax Withholding, Share-Based Payment Arrangement Accrued employee related costs Employee-related Liabilities, Current Other prepaid expenses Other Prepaid Expense, Current Line of Credit Line of Credit [Member] Restatement Determination Date Restatement Determination Date Agreement termination, contractual time threshold (in days) Agreement Termination, Contractual Time Threshold Agreement Termination, Contractual Time Threshold Other noncurrent liabilities Other Noncurrent Liabilities Other Noncurrent Liabilities Investment income and other, net Investment income and other, net Investment Income And Other Net Investment income and other net. Proceeds from sale of business Proceeds from Divestiture of Businesses Schedule of Prepaid Expenses Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Matthew Abernethy [Member] Matthew Abernethy Amendment Flag Amendment Flag External research and development External Research And Development [Member] External Research And Development Current liabilities: Liabilities, Current [Abstract] Liabilities related to assets held for sale: Disposal Group, Including Discontinued Operation, Liabilities [Abstract] Inventory [Axis] Inventory [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Developed product rights Developed Technology Rights [Member] Assets held for sale: Disposal Group, Including Discontinued Operation, Assets [Abstract] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Noncurrent inventory Inventory, Noncurrent Accrued interest related to repayment Interest Paid, Including Capitalized Interest, Operating and Investing Activities Unrealized loss Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Neurocrine Group Limited Neurocrine Group Limited [Member] Neurocrine Group Limited Other research and development Other Research And Development [Member] Other Research And Development Leases [Abstract] Leases [Abstract] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Property, Plant, and Equipment [Abstract] Entity Address, State or Province Entity Address, State or Province PEO Total Compensation Amount PEO Total Compensation Amount Common stock, par value (in USD per share) Common Stock, Par or Stated Value Per Share Intangible assets, net Intangible Asset, Excluding Goodwill, after Accumulated Amortization Share Repurchase Program [Domain] Share Repurchase Program [Domain] Basic (in shares) Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Accretion of discount on available-for-sale debt securities, net Accretion (Amortization) of Discounts and Premiums, Investments Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Number of reportable segments Number of Reportable Segments Total current liabilities Liabilities, Current 2030 Lessee, Operating Lease, Liability, to be Paid, Year Four Agreement termination, minimal contractual time (in days) Agreement Termination, Minimal Contractual Time Agreement Termination, Minimal Contractual Time Entity Address, City or Town Entity Address, City or Town Schedule of Supplemental Cash Flow Information Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Equity investments Equity Method Investments, Fair Value Disclosure Payroll and benefits Payroll And Benefits [Member] Payroll And Benefits Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total assets held for sale included in other current assets Disposal Group, Including Discontinued Operation, Assets Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Net product sales Product [Member] Net Carrying Amount Intangible Asset, Finite-Lived, after Accumulated Amortization Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Financing costs Debt Issuance Costs, Gross Net income - basic Net Income (Loss) Available to Common Stockholders, Basic Sublease income Sublease Income Accumulated Amortization Intangible Asset, Finite-Lived, Accumulated Amortization Level 2 Fair Value, Inputs, Level 2 [Member] Other income (expense): Nonoperating Income (Expense) [Abstract] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] 2026 Credit Facility 2026 Credit Facility [Member] 2026 Credit Facility Thereafter Intangible Asset, Finite-Lived, Estimated Amortization Expense, after Year Four Intangible Asset, Finite-Lived, Estimated Amortization Expense, after Year Four Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] 2029 Lessor, Operating Lease, Payment to be Received, Year Three Other Balance Sheet Details [Abstract] Other balance sheet details. Concentration Risk Type [Axis] Concentration Risk Type [Axis] Recently Issued Accounting Pronouncements Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Accrued capital expenditures Capital Expenditures Incurred but Not yet Paid Fair Value, Concentration of Risk [Table] Fair Value, Concentration of Risk [Table] Segment Reporting Segment Reporting [Table Text Block] Thereafter Lessor, Operating Lease, Payment to be Received, after Year Four Lessor, Operating Lease, Payment to be Received, after Year Four Amortization of deferred financing costs Amortization of Debt Issuance Costs Total inventory Inventory, Current And Noncurrent, Net Inventory, Current And Noncurrent, Net Repayments of borrowings under revolving credit facility Repayments of principal amount Repayments of Lines of Credit Less: Segment Reporting, Reconciliation [Abstract] Accrued development costs Accrued Research And Development Expense Current Accrued Research And Development Expense Current Schedule of Operating Lease Liability Maturity Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Document Period End Date Document Period End Date Holders of Soleno Common Stock Holders Of Soleno Common Stock [Member] Holders Of Soleno Common Stock Change in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Cash flows from investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding 2028 Lessee, Operating Lease, Liability, to be Paid, Year Two Stockholders’ Equity Equity [Text Block] Security Exchange Name Security Exchange Name Discount rate (as percent) Intangible Asset, Finite-Lived, Discount Rate Intangible Asset, Finite-Lived, Discount Rate Open Market Repurchases Open Market Repurchases [Member] Open Market Repurchases Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Shell Company Entity Shell Company Less current operating lease liabilities included in other current liabilities Operating Lease, Liability, Current Segment Reporting and Disaggregation of Relevant Expense Captions Segment Reporting, Policy [Policy Text Block] Sales rebates and reserves Provision for Loss on Contracts Earnings per Share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Earnings per share: Earnings Per Share [Abstract] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Total liabilities Liabilities Trading Symbol Trading Symbol Capital expenditures Payments to Acquire Property, Plant, and Equipment Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Patent term (in years) Patent Term Term of the patent, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Current income taxes payable Accrued Income Taxes, Current Schedule of Business Combination, Recognized Asset Acquired and Liability Assumed Business Combination, Recognized Asset Acquired and Liability Assumed [Table Text Block] Company Selected Measure Name Company Selected Measure Name Purchases of available-for-sale debt securities Payments to Acquire Debt Securities, Available-for-Sale Unrealized gain (loss) on available-for-sale debt securities, net of tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Outstanding borrowings Long-Term Debt, Gross Inventory step-up amortization period (in years) Business Combination, Inventory, Far Value Step-Up Adjustment, Amortization Period Business Combination, Inventory, Far Value Step-Up Adjustment, Amortization Period CRENESSITY net product sales CRENESSITY Net Product Sales [Member] CRENESSITY Net Product Sales Initial commitment fee rate (in percent) Line of Credit Facility, Commitment Fee Percentage Available-for-sale debt securities Debt Securities [Member] Credit Facility Credit Facility [Domain] Cash flows from operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Diluted (in shares) Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Entity Emerging Growth Company Entity Emerging Growth Company Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Disposal Group Name [Domain] Disposal Group Name [Domain] Total identifiable net assets acquired Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Line of Credit Facility [Table] Line of Credit Facility [Table] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Current branded prescription drug fee Accrued Branded Prescription Drug Fee Accrued Branded Prescription Drug Fee Proceeds from borrowings under revolving credit facility Proceeds from Lines of Credit Deferred income taxes Deferred Income Taxes and Tax Credits Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Disposal Groups, Including Discontinued Operations Disposal Groups, Including Discontinued Operations [Table Text Block] Royalties at tiered percentage (as a percent) Milestone Royalties At Tiered Percentage Milestone Royalties At Tiered Percentage Other assets and liabilities, net Increase (Decrease) in Other Operating Assets and Liabilities, Net Cash paid for amounts included in the measurement of operating lease liabilities Operating Lease, Payments Award Timing Predetermined Award Timing Predetermined [Flag] Other revenues Other Revenue, Royalty Earnings [Member] Other Revenue, Royalty Earnings Intangible Asset, Goodwill and Other [Abstract] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Level 1 Fair Value, Inputs, Level 1 [Member] Total operating lease payments (sublease income) Lessee, Operating Lease, Liability, to be Paid Fair Value Measurements Fair Value of Financial Instruments, Policy [Policy Text Block] Effect of dilutive securities (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements All Executive Categories All Executive Categories [Member] Repurchases of common stock Total cost of shares Stock Repurchased and Retired During Period, Value Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Preferred stock, par value (in USD per share) Preferred Stock, Par or Stated Value Per Share Depreciation Depreciation Intangible assets, net Disposal Group, Including Discontinued Operation, Intangible Assets Right-of-use assets Operating Lease, Right-of-Use Asset Concentration Risk Type [Domain] Concentration Risk Type [Domain] Earnings per share: Earnings Per Share, Basic and Diluted EPS [Abstract] Earnings Per Share, Basic and Diluted EPS VYKAT XR net product sales VYKAT XR Net Product Sales [Member] VYKAT XR Net Product Sales Schedule of Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Total assets acquired and liabilities assumed Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Instrument, Name Debt Instrument, Name [Domain] Segment Reporting and Disaggregation of Relevant Expense Captions Segment Reporting [Text Block] Minimum Minimum [Member] Sublease Income Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Abstract] Nxera Nxera Pharma UK Limited [Member] Nxera Pharma UK Limited Expiration Date Trading Arrangement Expiration Date Schedule of Future Annual Amortization Expense for Finite-Lived Intangible Assets Intangible Asset, Finite-Lived, Amortization Expense [Table Text Block] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Weighted-average shares outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Disposal Group, Including Discontinued Operations [Line Items] Disposal Group, Including Discontinued Operations [Line Items] Accounts payable and accrued liabilities Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities Business Combination [Line Items] Business Combination [Line Items] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Issuances of common stock under benefit plans Proceeds from Issuance of Common Stock Common stock, shares authorized (in shares) Common Stock, Shares Authorized Accounts receivable Business Combination, Recognized Asset Acquired, Receivable, Current Useful life of developed product rights (in years) Intangible Asset, Finite-Lived, Useful Life Takeda Takeda Pharmaceutical Company Limited [Member] Takeda Pharmaceutical Company Limited Exercise Price Award Exercise Price Cash flows from investing activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Segment Reporting [Line Items] Segment Reporting [Line Items] Share repurchase program, authorized, amount Share Repurchase Program, Authorized, Amount Net income (loss) Business Combination, Pro Forma Information, Pro Forma Income (Loss), after Tax Sales and maturities of available-for-sale debt securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Document Quarterly Report Document Quarterly Report 2027 Lessor, Operating Lease, Payment to be Received, Year One Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Segments [Domain] Segments [Domain] Sale of stock (in shares) Sale Of Stock, Number Of Shares Sold In Transaction The number of shares sold by the collaboration partner per stock transaction. Convertible Senior Notes Debt Disclosure [Text Block] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Debt issuance costs Debt Issuance Costs, Net Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Business Combination [Table] Business Combination [Table] Equity Component Equity Component [Domain] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] Total operating expenses Costs and Expenses Adoption Date Trading Arrangement Adoption Date Cash consideration Disposal Group, Including Discontinued Operation, Consideration Counterparty Counterparty Name [Domain] Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Total other income, net Nonoperating Income (Expense) Disposal Group, Disposed of by Sale, Not Discontinued Operations Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Eric Benevich [Member] Eric Benevich Assets Assets [Abstract] Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount 2023 Voyager Agreement 2023 Voyager Agreement [Member] 2023 Voyager Agreement Accounting Policies [Abstract] Accounting Policies [Abstract] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Total operating lease liabilities Operating Lease, Liability Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Noncurrent income taxes payable Accrued Income Taxes, Noncurrent Share Repurchase Programs Share Repurchase Programs [Member] Share Repurchase Programs Selling, general, and administrative Selling, general, and administrative Selling, General and Administrative Expense Supplemental Financial Information Supplemental Balance Sheet Disclosures [Text Block] Patents Patents [Member] Business Combination [Domain] Business Combination [Domain] Letter of Credit Letter of Credit [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Number of operating segments Number of Operating Segments Shares excluded from diluted per share amounts because their effect would have been anti-dilutive (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of the Carrying Amount of Goodwill Goodwill [Table Text Block] Entity Central Index Key Entity Central Index Key Additional paid-in capital Additional Paid in Capital, Common Stock All Adjustments to Compensation All Adjustments to Compensation [Member] Other Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Other Item Business Combination [Axis] Business Combination [Axis] Equity [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Cash flows from operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Accounts Receivable Accounts Receivable [Member] VYKAT XR VYKAT XR [Member] VYKAT XR Legal Matters Legal Matters and Contingencies [Text Block] Total liabilities related to assets held for sale included in other current liabilities Disposal Group, Including Discontinued Operation, Liabilities Income Statement [Abstract] Income Statement [Abstract] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Document Transition Report Document Transition Report Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Investment, Name Investment, Name [Axis] Share Repurchase Program [Table] Share Repurchase Program [Table] Operating expenses: Operating Expenses [Abstract] Deferred tax assets Deferred Income Tax Assets, Net Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Schedule of Information Relating to our Recognized Intangible Assets Intangible Asset, Finite-Lived [Table Text Block] Credit facility borrowing (in percent) Debt Instrument, Basis Spread on Variable Rate City Area Code City Area Code Accumulated Other Comprehensive Income AOCI Attributable to Parent [Member] All Individuals All Individuals [Member] Non-cash lease expense Operating Lease, Right-of-Use Asset, Periodic Reduction Collaborative Arrangement Collaborative Arrangement [Member] Name Forgone Recovery, Individual Name Fair Value, Concentration of Risk, Financial Statement Captions [Line Items] Fair Value, Concentration of Risk, Financial Statement Captions [Line Items] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Purchase price for the soleno acquisition related to soleno shares Business Combination, Consideration Transferred, Equity Interest Statement [Line Items] Statement [Line Items] Total assets Assets Operating Leases Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Business Combination [Abstract] Business Combination [Abstract] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Interest expense Interest expense Interest Expense, Nonoperating Accounts payable and other accrued liabilities Accounts Payable and Other Accrued Liabilities, Current PEO PEO [Member] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Share-based compensation expense Share-Based Payment Arrangement, Expense Repurchases of common stock (in shares) Number of shares (in shares) Stock Repurchased and Retired During Period, Shares Other noncurrent liabilities Total other noncurrent liabilities Other Liabilities, Noncurrent Goodwill Goodwill, at beginning period Goodwill, at ending period Goodwill Inventory Business Combination, Recognized Asset Acquired, Inventory, Current Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Additions in connection with the acquisition of Soleno Therapeutics, Inc. Goodwill, Acquired During Period Retained Earnings (Accumulated Deficit) Retained Earnings [Member] Noncurrent operating lease liabilities Noncurrent operating lease liabilities Operating Lease, Liability, Noncurrent Revolving Credit Facility Revolving Credit Facility [Member] Cash and cash equivalents Business Combination, Recognized Asset Acquired, Cash and Cash Equivalent Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Agreement termination by counterparty, contractual time threshold (in days) Agreement Termination By Counterparty, Contractual Time Threshold Agreement Termination By Counterparty, Contractual Time Threshold Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Award Timing Disclosures [Line Items] Payment of debt issuance costs Payments of Debt Issuance Costs Diluted (in USD per share) Earnings Per Share, Diluted Entity Current Reporting Status Entity Current Reporting Status Soleno Therapeutics, Inc. Soleno Therapeutics, Inc. [Member] Soleno Therapeutics, Inc. Cash flows from financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Total Shareholder Return Amount Total Shareholder Return Amount Inventory [Domain] Inventory [Domain] Amortization of acquired intangible assets Intangible Asset, Finite-Lived, Amortization Expense Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Schedule of Business Combination Business Combination [Table Text Block] Research and development Research and Development Expense Borrowings Proceeds from Long-Term Lines of Credit Schedule of Business Combination, Pro Forma Information Business Combination, Pro Forma Information [Table Text Block] Adjustments to reconcile net income to net cash from operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Milestones Milestones [Member] Milestones Cash flows from financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Total revenues Total revenues Revenue from Contract with Customer, Excluding Assessed Tax Property and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Available borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Financial Instruments Financial Instruments [Domain] Collaboration revenues Collaboration Revenue [Member] Collaboration revenue. Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Customer, Extent of Reliance Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Customer, Extent of Reliance [Table Text Block] Intangible Asset, Finite-Lived, Class Intangible Asset, Finite-Lived, Class [Axis] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Share Repurchase Program [Line Items] Share Repurchase Program [Line Items] Goodwill and Intangible Assets Intangible Asset and Goodwill [Text Block] Underlying Securities Award Underlying Securities Amount Prepaid expenses Total prepaid expenses Prepaid Expense, Current Number of preclinical candidates Number Of Preclinical Candidates Number Of Preclinical Candidates Inventory Increase (Decrease) in Inventories 2019 Voyager Agreement 2019 Voyager Agreement [Member] 2019 Voyager Agreement Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Segment Reporting [Table] Segment Reporting [Table] Intangible Assets [Line Items] Intangible Assets [Line Items] Intangible Assets Total revenues to soleno Business Combination, Acquiree's Revenue since Acquisition Date, Actual Schedule of Operating Lease Lease, Cost [Table Text Block] Other current assets Other Assets, Current Other assets and liabilities, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Operating income Operating Income (Loss) Current Fiscal Year End Date Current Fiscal Year End Date Gain on sale of business, net of transaction costs Gain on sale of business, net of transaction costs Gain (Loss) on Disposition of Business Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Acquisition of Soleno Therapeutics, Inc. Business Combination [Text Block] Reportable Segment Reportable Segment [Member] Reportable Segment Holders of Soleno Equity Awards Holders Of Soleno Equity Awards [Member] Holders Of Soleno Equity Awards Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Entity File Number Entity File Number Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Prepaid development costs Prepaid Development Costs Prepaid Development Costs Issuances of common stock under benefit plans, net of tax Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Equity investments Equity Securities [Member] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Common stock, shares issued (in shares) Common Stock, Shares, Issued Measure: Measure [Axis] Finished goods Inventory, Finished Goods, Gross Sanofi S.A Sanofi S.A [Member] Sanofi S.A Cost of revenues, excluding amortization of acquired intangible assets Cost of revenues, excluding amortization of acquired intangible assets Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization Available-for-sale debt securities Debt Securities, Available-for-Sale, Current Equity Components Equity Components [Axis] Accounts receivable Increase (Decrease) in Accounts Receivable Product and Service Product and Service [Domain] Entity Interactive Data Current Entity Interactive Data Current Net income (loss) attributable to soleno Business Combination, Acquiree's Earnings (Loss) since Acquisition Date, Actual Deferred tax liabilities Deferred Income Tax Liabilities, Net Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Accounts payable and accrued liabilities Total accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Entity Small Business Entity Small Business Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent 2029 Lessee, Operating Lease, Liability, to be Paid, Year Three Termination Date Trading Arrangement Termination Date Property, Plant, and Equipment [Line Items] Property, Plant, and Equipment [Line Items] Accounts payable and accrued liabilities Business Combination, Recognized Liability Assumed, Accounts Payable and Accrued liabilities, Current Business Combination, Recognized Liability Assumed, Accounts Payable and Accrued liabilities, Current Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Intangible Assets [Table] Intangible Assets [Table] Intangible Assets Intangible assets Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Finite-Lived Sale of Neurocrine Group Limited Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Organization and Significant Accounting Policies Business Description and Accounting Policies [Text Block] Income tax assets and liabilities Increase (Decrease) in Income Taxes Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Other current liabilities Other Liabilities, Current Other noncurrent assets Other Assets, Noncurrent Document Type Document Type Acquisition of business, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Inventory fair value, step-up Business Combination, Inventory, Fair Value Step-Up Adjustment Business Combination, Inventory, Fair Value Step-Up Adjustment Fair Value as of Grant Date Award Grant Date Fair Value Finished Goods Finished Goods [Member] Finished Goods Schedule of Information Relating to our Recognized Intangible Assets Intangible Asset, Indefinite-Lived [Table Text Block] Acquired in-process research and development Acquired in-process research and development Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Authorized amount remaining under program Share Repurchase Program, Remaining Authorized, Amount Cash and cash equivalents Cash and Cash Equivalents [Member] Arrangement Duration Trading Arrangement Duration Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Local Phone Number Local Phone Number Work in process Inventory, Work in Process, Gross Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name INGREZZA net product sales INGREZZA Net Product Sales [Member] INGREZZA Net Product Sales Right-of-use assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Assets Amortization of inventory fair-value step-up Amortization Of Inventory Fair Value Step Up Amortization Of Inventory Fair Value Step Up Income before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Gross Carrying Amount Intangible Asset, Finite-Lived, before Accumulated Amortization Schedule of Other Noncurrent Liabilities Other Noncurrent Liabilities [Table Text Block] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] 2030 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Four Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Potential milestone payments Potential Milestone Payments The amount of potential milestone payments under a collaborative arrangement. Executive Category: Executive Category [Axis] Goodwill [Roll Forward] Goodwill [Roll Forward] Counterparty Counterparty Name [Axis] Liabilities and Stockholders' Equity Liabilities and Equity [Abstract] Intangible Asset, Finite-Lived, Class Intangible Asset, Finite-Lived, Class [Domain] Number of undisclosed programs Number Of Undisclosed Programs Number Of Undisclosed Programs 2030 Lessor, Operating Lease, Payment to be Received, Year Four Inventory Inventory, Net All Award Types Award Type [Domain] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount 2026 (6 months remaining) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Fair Value Measurements Fair Value Disclosures [Text Block] 2027 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year One Share price (in USD per share) Share Price PEO Name PEO Name Restricted cash related to leases Restricted Cash Total operating lease payments (sublease income) Lessor, Operating Lease, Payment to be Received Cash paid for income taxes Income Tax Paid, before Refund Received Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Entity Tax Identification Number Entity Tax Identification Number Interest expense Interest Expense, Debt Noncurrent available-for-sale debt securities Debt Securities, Available-for-Sale, Noncurrent Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Total cash, cash equivalents, and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Customer C Customer C [Member] Customer C Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Non-NEOs Non-NEOs [Member] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Debt Instrument Debt Instrument [Axis] Beneficial ownership (as a percent) Equity Method Investment, Ownership Percentage Cash paid to Soleno stockholders Payments to Acquire Businesses, Gross Stock-based compensation Share-Based Payment Arrangement, Noncash Expense 2028 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Two Disposal Group Name [Axis] Disposal Group Name [Axis] Number of gene therapy programs Number Of Gene Therapy Programs Number Of Gene Therapy Programs Investment, Name Investment, Name [Domain] Customer [Domain] Customer [Domain] Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Leases Lessee, Operating Leases [Text Block] Long-Term Debt, Type [Domain] Long-Term Debt, Type [Domain] Basic (in USD per share) Earnings Per Share, Basic Raw materials Inventory, Raw Materials, Gross Repurchases of common stock Payments for Repurchase of Common Stock Total current assets Assets, Current Operating lease liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities Statistical Measurement Statistical Measurement [Axis] Insider Trading Arrangements [Line Items] Award Type Award Type [Axis] 2026 (6 months remaining) Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Schedule Class of Treasury Stock Class of Treasury Stock [Table Text Block] Retained earnings Retained Earnings (Accumulated Deficit) Product and Service Product and Service [Axis] Equity investments Equity Securities, FV-NI Restricted cash included in other noncurrent assets Restricted Cash, Noncurrent Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Common Stock Common Stock [Member] Gain on sale of business, net of transaction costs Gain on disposal Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Available-for-sale debt securities Debt Securities, Available-for-Sale Operating lease cost Operating Lease, Cost Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Cover [Abstract] Cover [Abstract] Net operating lease cost Operating Leases, Rent Expense, Net Sublease Income Operating Leases, Rent Expense, Net Sublease Income Concentration risk, percentage Concentration Risk, Percentage Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Foreign currency translation adjustments Goodwill, Foreign Currency Translation, Gain (Loss) Equity Awards Adjustments Equity Awards Adjustments [Member] Collaboration and License Agreements Collaborative Arrangement Disclosure [Text Block] Realized loss on sale of available-for-sale debt securities Debt Securities, Available-for-Sale, Realized Gain (Loss) Total liabilities and stockholders’ equity Liabilities and Equity George Morrow [Member] George Morrow Employee Stock Option Share-Based Payment Arrangement, Option [Member] Customer D Customer D [Member] Customer D Segments [Axis] Segments [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Agreement termination by counterparty, minimal contractual time (in days) Agreement Termination By Counterparty, Minimal Contractual Time Agreement Termination By Counterparty, Minimal Contractual Time Tabular List, Table Tabular List [Table Text Block] 2029 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Three Schedule of Accounts Payable and Accrued Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Voyager Voyager Therapeutics [Member] Voyager therapeutics. 2026 (6 months remaining) Intangible Asset, Finite-Lived, Estimated Amortization Expense, Remainder of Fiscal Year Name Awards Close in Time to MNPI Disclosures, Individual Name Foreign currency translation adjustments, net of tax Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Property, Plant, and Equipment [Table] Property, Plant, and Equipment [Table] Thereafter Lessee, Operating Lease, Liability, Payments, Due After Year Four Lessee, Operating Lease, Liability, Payments, Due After Year Four Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding Preferred Stock, Value, Issued Adjustment to Compensation: Adjustment to Compensation [Axis] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activity Prepaid income taxes Prepaid Taxes Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Credit Facility Credit Facility [Axis] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Fair value of assets on recurring basis Assets, Fair Value Disclosure Total Gross Product Sales Revenue, Product and Service Benchmark [Member] Discontinued Operations and Disposal Groups [Abstract] Name Measure Name Pay vs Performance Disclosure [Line Items] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Total preliminary consideration transferred Business Combination, Consideration Transferred Additional Paid-In Capital Additional Paid-in Capital [Member] Entity Filer Category Entity Filer Category Fair value Debt Securities, Available-for-Sale, Unrealized Loss Position Name Trading Arrangement, Individual Name Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalent Board of directors maximum duration term (in years) Board Of Directors Maximum Duration Term Board Of Directors Maximum Duration Term Interest rate during period Debt Instrument, Interest Rate During Period Customer B Customer B [Member] Customer B Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Company Selected Measure Amount Company Selected Measure Amount Unrealized gain (loss) on equity investments Changes in fair values of equity investments Unrealized (gain) loss on equity investments Equity Securities, FV-NI, Unrealized Gain (Loss) Variable rate Debt Instrument, Variable Rate Debt Instrument, Variable Rate Inventory, gross Inventory, Gross Issuances of common stock under stock plans (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Business combination (in dollars per share) Business Combination, Price Per Share Current assets: Assets, Current [Abstract] Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Revenues Business Combination, Pro Forma Information, Pro Forma Revenue Non-PEO NEO Non-PEO NEO [Member] Entity Address, Address Line One Entity Address, Address Line One Right-of-use assets acquired through operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Provision for income taxes Provision for income taxes Income Tax Expense (Benefit) Xenon Xenon Pharmaceuticals Inc. [Member] Xenon Pharmaceuticals Inc. Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Customer Concentration Risk Customer Concentration Risk [Member] Award Timing Method Award Timing Method [Text Block] Change in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and development Total research and development Research and Development Expense (Excluding Acquired in Process Cost) Amortization of inventory step-up Amortization Of Inventory Step-Up Amortization Of Inventory Step-Up Deferred tax liabilities Business Combination, Recognized Liability Assumed, Deferred Tax Liability 2028 Lessor, Operating Lease, Payment to be Received, Year Two Accrued interest receivables Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss Customer A Customer A [Member] Customer A Net income Net income Net income Net Income (Loss) Attributable to Parent Long-Term Debt, Type [Axis] Long-Term Debt, Type [Axis] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Statement [Table] Statement [Table] Restatement Determination Date: Restatement Determination Date [Axis] Other liabilities Disposal Group, Including Discontinued Operation, Other Liabilities Revenues: Revenues [Abstract] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Prepaid expenses and other current assets Business Combination, Recognized Asset Acquired, Prepaid Expense and Other Asset, Current